Phase II funding BEL recently secured $2.2M in Phase II funding from the National Institutes of Aging to support an FDA-monitored clinical trial for Electric Sleep Therapy. This indicates active government-backed research and potential near-term demand for clinical-grade equipment, services, and regulatory guidance.

Clinical trial The collaboration with Neurosom on an FDA-monitored trial targeting deep sleep and memory consolidation in seniors with Mild Cognitive Impairment points to opportunities in sleep research hardware, data capture systems, analytic software, and monitoring solutions suitable for elderly cohorts.

Healthcare alignment BEL’s focus on brain function research, training of University of Oregon students, and SBIR-driven technology exploration aligns with potential partnerships for beta deployments, pilot programs, and government-funded R&D contracts in neurodiagnostics and neurostimulation domains.

Moderate scale With a small-to-mid-sized team (11-50 employees) and revenue in the low-to-mid millions, BEL presents a prime target for enterprise-incremental sales: upgrading instrumentation, lab automation, regulatory-compliant data handling, and service packages tailored to small research labs.

Tech stack fit Adoption of modern web and development practices (Laravel, Stimulus, parallax.js, Google tools) suggests receptivity to software-enabled products such as data management platforms, remote monitoring dashboards, and SBIR-friendly software licenses that integrate with existing lab workflows.